Project Grant HT94252510482
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$590K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Princeton, NJ 08544, USA
Similar Awards
This $2,065,452 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports an epigenetic and innate immune memory research project at the Icahn School of Medicine at Mount Sinai. The project aims to develop a pathophysiologically based diagnostic biomarker signature for Gulf War Illness, with a performance period from Jul 1, 2025 to Jun 30, 2028. The research will investigate an epigenetic innate immune...
The Defense Health Agency awarded Duke University a $759,627.49 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "ACCELERATED AGING IN GULF WAR ILLNESS: PHENOTYPES, EPIGENETIC BIOMARKERS, AND ASSOCIATIONS WITH GULF WAR EXPOSURES." The project will run from August 1, 2023 to July 31, 2026. Duke University, a top-ranked global research institution, will be the prime awardee and perform the research through its Office of...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $713,277 to Boston University Medical Campus to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness. The award will support the project from September 1, 2024 through August 31, 2027. As part of this...
This Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), provides $1,704,652.00 to Trustees of Boston University (Boston University Medical Campus) to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness (GWI). The award period runs from September 1, 2024 to August...
This federal Project Grant award, valued at $707,436.00 and provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports research at the Albert Einstein College of Medicine to investigate biomarker signatures related to post-traumatic epileptogenesis (PTEGENESIS) and treatments. The project has an award date of May 1, 2025 and an ultimate completion date of April 30, 2027. Additionally, the award includes a sub-grant...
The federal Project Grant award, totaling $6,663,794.00 and effective September 30, 2024, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the "PRECISIE RTD TRIAL: PRECISION WITH RETURN-TO-DUTY DECISIONS IN THE MILITARY" research initiative, which aims to transform healthcare for military service members. The primary awardee, The Geneva Foundation, will conduct advanced biomedical research and...
This federal Project Grant award of $1,539,865.00, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research at the University of Utah to confirm the effectiveness of acupuncture in treating the symptoms of Gulf War Illness. The project, set to run from August 1, 2024 to July 31, 2028, will leverage the university's expertise in biomedical research and healthcare services to advance knowledge in this critical area. The...
The Department of the Army Medical Command awarded a $564,698.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Texas A&M Engineering Experiment Station (Tees) to develop "Engineered Therapeutic Extracellular Vesicles to Resolve Pyridostigmine Bromide-Induced Enteric Neuroinflammation in Gulf War Illness." The grant, with a performance period from November 1, 2024 to October 31, 2027, will support advanced biomedical research...
The Defense Health Agency has awarded a $760,844.00 Project Grant to the Texas A&M University System Health Science Center to conduct research under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, awarded on September 15, 2023 with a completion date of September 14, 2026, will fund research titled "Targeting the MIF/CD74 Immune Axis to Treat GWI Astrocyte, Neuronal, and Cognitive Dysfunction." This research aims to investigate medical...
This $1,994,937 federal Project Grant award, funded by the U.S. Department of Defense through the Military Medical Research and Development program (CFDA 12.420), is supporting research to confirm the effectiveness of acupuncture in treating the symptoms of Gulf War Illness. The grant recipient, Beth Israel Deaconess Medical Center, Inc. (Bidmc), a prominent academic medical center in Boston, will conduct this research project over a 4-year period from August 2024 to July 2028. Bidmc has...